40bySVqeo7y health.huanqiu.comgallery艾伯维携五大领域创新成果首次亮相进博会 将构建立体医疗创新生态圈/e3pmt7dq2/e3pn6gvs71604790193482环球网版权作品,未经书面授权,严禁转载或镜像,违者将被追究法律责任。责编:沙 琼环球网160479019348211[]{"audio":{"members":[]},"gallery":{"members":[{"desc":"11月5日,全球排名前十的研究型生物制药公司艾伯维(AbbVie)携免疫学、肿瘤学、神经科学、眼科学及艾尔建美学5大核心领域创新成果首次亮相进博会。这是今年5月刚刚完成了对艾尔建里程碑式收购之后,全新艾伯维的首次登场。艾伯维在本届进博会以“超凡实验室“为概念,在500平方米的主展台全方位展现艾伯维的五大“超凡”——超凡展台设计、超凡研发实力、超凡创新疗法、超凡合作格局、超凡人才战略。","height":360,"id":"a6d9824ac2b283bc1384960a9f58ffb6u5","mime":"image\/jpeg","size":66.21,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/a6d9824ac2b283bc1384960a9f58ffb6u5.jpg","width":640},{"desc":"11月5日,艾伯维中国总经理欧思朗(左)与艾伯维旗下艾尔建美学中国总经理丘汉华(右)共同为展台揭幕。","height":360,"id":"9d55e756b44803064cf4d887d8c5c31fc5","mime":"image\/jpg","size":81501,"url":"//img.huanqiucdn.cn/dp/api/files\/image\/9d55e756b44803064cf4d887d8c5c31fc5.jpg","width":640},{"desc":"在今年首设的“公共卫生防疫专区“,以“疫路有艾,风雨同行”为主题,在100平方米的展台展现艾伯维在中国及全球抗击新冠肺炎疫情过程中所做的努力。","height":360,"id":"ab93fad77f46c14fb9ab73554e59b0b2u5","mime":"image\/jpeg","size":73.93,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/ab93fad77f46c14fb9ab73554e59b0b2u5.jpg","width":640},{"desc":"观展群众驻足观看艾伯维抗疫展区。","height":360,"id":"3248c3aace9c68401600173b5f199334u5","mime":"image\/jpeg","size":78.38,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/3248c3aace9c68401600173b5f199334u5.jpg","width":640},{"desc":"艾伯维主展区台人头攒动。","height":1080,"id":"646ba362c2c6f5deaee12f64c3c643a3u0","mime":"image\/jpeg","size":202.85,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/646ba362c2c6f5deaee12f64c3c643a3u0.jpeg","width":1440},{"desc":"艾伯维旗下产品的修美乐(阿达木单抗注射液)是全球首个获批的全人源抗肿瘤坏死因子(TNF-α)单抗,主要用于治疗类风湿关节炎、强直性脊柱炎和银屑病等自身免疫疾病,2002年在美国获批上市后获得广泛关注,并在2012年以92.65亿美元的销售额名列全球处方药第一位,至2020年已是连续第8年排名第一,2019年全球销售额近200亿美元。","height":1440,"id":"60134d7cfd24839501a816eca45fdff9u0","mime":"image\/jpeg","size":114.21,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/60134d7cfd24839501a816eca45fdff9u0.jpeg","width":1080},{"desc":"修美乐®在华上市10年,已进入风湿免疫科、皮肤科、儿科、消化科、眼科等五大领域,目前已获批七个适应症:2010年获批类风湿关节炎,2013年获批强直性脊柱炎,2017年获批中重度斑块状银屑病,2019年获批多关节型幼年特发性关节炎,2020年获批中重度活动性克罗恩病、葡萄膜炎和儿童银屑病。2019年11月,修美乐®进入中国医保乙类目录,覆盖类风湿关节炎、强直性脊柱炎和中重度斑块状银屑病。","height":1440,"id":"681411ce4eaf42ab8d444c458beaee48u0","mime":"image\/jpeg","size":72.58,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/681411ce4eaf42ab8d444c458beaee48u0.jpeg","width":1080},{"desc":"记者现场佩戴“类风湿关节炎手套“体验患者日常。没有带上手套时,握压力球很轻松。","height":1440,"id":"baf8f8c5a9ceaaf876b186259b3d9711u0","mime":"image\/jpeg","size":74.84,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/baf8f8c5a9ceaaf876b186259b3d9711u0.jpeg","width":1080},{"desc":"记者戴上“类风湿关节炎手套“手套后,握紧压力球都变成一件很费劲的事。","height":1440,"id":"7b4f552a5697ebcdf7a61dc8ae9f92b7u0","mime":"image\/jpeg","size":82.83,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/7b4f552a5697ebcdf7a61dc8ae9f92b7u0.jpeg","width":1080},{"desc":"进入博鳌先行试用区的艾伯维青光眼引流管XEN(左侧针管),也是唯一一个目前通过真实事件获批进入中国的医疗产品。","height":927,"id":"69db61bd72ac132e1bd1b21356e8d41au5","mime":"image\/jpeg","size":70.47,"url":"//img.huanqiucdn.cn/dp/api/files\/imageDir\/69db61bd72ac132e1bd1b21356e8d41au5.jpg","width":1028}]},"video":{"members":[]}}//img.huanqiucdn.cn/dp/api/files/imageDir/7540da56e53d23853f9d01baed4c4964u1.png